Literature DB >> 25087153

The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey.

Mauro Molteni1, Hernan Polo Friz2, Laura Primitz2, Giuseppe Marano3, Patrizia Boracchi3, Claudio Cimminiello2.   

Abstract

AIMS: To assess different aspects of the definition of valvular/non-valvular atrial fibrillation (AF) used in clinical practice by physicians who usually treat this condition. METHODS AND
RESULTS: We prospectively conducted a web-based survey including cardiologists and internists who attended continuing medical education courses on cardiovascular medicine. A questionnaire was drawn up, containing 17 questions clustered into five main topics: (A) known rheumatic aetiology; (B) site/type of valve involvement; (C) prosthetic heart valve; (D) haemodynamic relevance; (E) miscellaneous. The overall response rate was 22.4% (21.1% for cardiologists and 24% for internists). Coexistence of both medical history of rheumatic disease and clinical signs of valvular involvement were considered as essential prerequisites for the diagnosis of rheumatic AF by half of the respondents, and one-third assumed that lone aortic valve disease was sufficient for AF to be defined as valvular. A similar proportion of respondents considered that in the presence of mitral regurgitation, AF had to be defined as valvular. The majority of responding physicians considered the degree of valvular defect of lesser importance for the definition of valvular or non-valvular origin of AF.
CONCLUSION: We found important heterogeneity and uncertainties in the answers given by physicians who usually treat patients with AF, as evidence of the lack of precise and unique definitions of the origin of AF (valvular/non-valvular). It is urgent to issue clear widely accepted definitions of the origin of AF, which should improve clinical practice and research. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Anti-thrombotic therapy; Atrial fibrillation; Non-valvular; Stroke; Survey; Valvular

Mesh:

Year:  2014        PMID: 25087153     DOI: 10.1093/europace/euu178

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  9 in total

1.  Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.

Authors:  Domenico Acanfora; Chiara Acanfora; Pietro Scicchitano; Marialaura Longobardi; Giuseppe Furgi; Gerardo Casucci; Bernardo Lanzillo; Ilaria Dentamaro; Annapaola Zito; Raffaele Antonelli Incalzi; Marco Matteo Ciccone
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

2.  Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?

Authors:  Giuseppe Di Pasquale; Silvia Zagnoni; Letizia Riva
Journal:  Intern Emerg Med       Date:  2015-01-15       Impact factor: 3.397

Review 3.  Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era.

Authors:  Daniel Hammersley; Mark Signy
Journal:  Ther Adv Chronic Dis       Date:  2017-07-26       Impact factor: 5.091

4.  Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.

Authors:  Özcan Başaran; Volkan Dogan; Osman Beton; Mehmet Tekinalp; Ahmet Çağrı Aykan; Ezgi Kalaycıoğlu; Ismail Bolat; Onur Taşar; Özgen Şafak; Macit Kalçık; Mehmet Yaman; Sinan İnci; Bernas Altıntaş; Sedat Kalkan; Cevat Kırma; Murat Biteker
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

Review 5.  Percutaneous Left Atrial Appendage Closure: is there a Role in Valvular Atrial Fibrillation.

Authors:  Chetan Huded; Amar Krishnaswamy; Samir Kapadia
Journal:  J Atr Fibrillation       Date:  2017-02-28

Review 6.  Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.

Authors:  Luigi Di Biase
Journal:  J Am Heart Assoc       Date:  2016-02-18       Impact factor: 5.501

7.  Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.

Authors:  Alexander C Fanaroff; Amit N Vora; Renato D Lopes
Journal:  Eur Heart J Suppl       Date:  2022-02-14       Impact factor: 1.803

8.  Computational fluid dynamics modelling of left valvular heart diseases during atrial fibrillation.

Authors:  Stefania Scarsoglio; Andrea Saglietto; Fiorenzo Gaita; Luca Ridolfi; Matteo Anselmino
Journal:  PeerJ       Date:  2016-07-26       Impact factor: 2.984

9.  Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation.

Authors:  Alexander Birkinshaw; Christopher H Fry; David Fluck; Pankaj Sharma; Thang S Han
Journal:  JRSM Cardiovasc Dis       Date:  2020-03-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.